New monthly weight loss shot shows promise in Mid-Stage trial

NCT ID NCT06973720

Ongoing Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called MET097, given as a shot, to help people with obesity or overweight lose weight. After 12 weekly doses, participants switch to monthly shots for up to 64 weeks. The trial compares four different dose schedules against a placebo to see which works best and is safest. About 268 people without type 2 diabetes are taking part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MET097 (a weight loss drug given as a shot)
What this could lead to: If successful, this could lead to a monthly injection for weight loss, offering a more convenient option than weekly shots.
What could go wrong: This is a mid-stage trial with only 268 people, so results may not hold in larger studies. Side effects are possible, and the drug may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY OVERWEIGHT OR OBESITY

Contacts and locations

Locations

CenExel iResearch, LLC

Decatur, Georgia, 30030, United States
CenExel iResearch, LLC

Savannah, Georgia, 31405, United States
ForCare Clinical Research

Tampa, Florida, 33613, United States
Hassman Research Institute

Marlton, New Jersey, 08053, United States
Research Centers of America

Hollywood, Florida, 33024, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.